Advertisement

Scleroderma

  • Catherine H. Orteu
  • Jan P. Dutz
  • Nicolas Hunzelmann
  • Thomas Krieg

Abstract

Localized scleroderma (LS) or morphea encompasses a group of disorders characterized by limited and localized inflammatory sclerosis (thickening) and fibrosis of the skin, subcutaneous tissue, fascia and/or adjacent muscle. In contrast to systemic sclerosis, Raynaud’s phenomenon, acrosclerosis and internal organ involvement do not usually occur. Morphea may be divided into five subtypes: plaque, generalized, bullous, linear and deep, based on the extent, form and depth of cutaneous sclerosis (Peterson et al. 1995). These subtypes frequently occur together in the same patient. Although morphea is rarely life threatening, significant morbidity and disability occur, particularly in the linear and deep forms.

Keywords

Systemic Sclerosis Connective Tissue Growth Factor Lichen Sclerosus Progressive Systemic Sclerosis Localize Scleroderma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aberer E, Neumann R, and Stanek G (1985) Is localised scleroderma a Borrelia infection? Lancet, 2: 278PubMedCrossRefGoogle Scholar
  2. Aiba S, Tabata N, Ohtani H, Tagami H (1994) CD34+ spindle-shaped cells selectively disappear from the skin lesion of scleroderma. Arch Dermatol, 130: 593–597PubMedCrossRefGoogle Scholar
  3. Arnett FC, Tan FK, Uziel Y, Laxer RM, Krafchik BR, Antohi S, and Bona C (1999) Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin 1, in patients with localized scleroderma. Arthritis Rheum, 42: 2656–2659PubMedCrossRefGoogle Scholar
  4. Balat A, Akinci A, Turgut M, Mizrak B, Aydin A (1999) Eosinophilic fasciitis–progression to linear scleroderma: a case report. Turk J Pediatr, 41: 381–385PubMedGoogle Scholar
  5. Barrera P, Haagsma CJ, Boerbooms AM, Van Riel PL, Borm GF, Van de Putte LB, Van der Meer JW (1995) Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis. Br J Rheumatol, 34: 747–755Google Scholar
  6. Blaszczyk M, Jablonska S (1999) Linear scleroderma en coup de sabre. Relationship with progressive facial hemiatrophy (PFH). RheumaDerm, M. a. Uitto, ed., Kluwer Academic/ Plenum Publishers, New York, 101–104Google Scholar
  7. Blaszczyk M, Krysicka-Janiger K, Jablonska S (2000) Primary atrophic profound linear scleroderma. Report of three cases. Dermatology, 200. 63–66Google Scholar
  8. Bleasel NR, Stapleton KM, Commens C, Ahern VA (1999) Radiation-induced localized scleroderma in breast cancer patients. Australas J Dermatol, 40: 99–102PubMedCrossRefGoogle Scholar
  9. Bodemer C, Belon M, Hamel-Teillac D, Amoric JC, Fraitag S, Prieur AM, De Prost Y (1999) Scleroderma in children: a retrospective study of 70 cases. Ann Dermatol Venereol, 126: 691–694PubMedGoogle Scholar
  10. Boelsma E, Pavel S, Ponec M (1995) Effects of calcitriol on fibroblasts derived from skin of scleroderma patients. Dermatology, 191: 226–33PubMedCrossRefGoogle Scholar
  11. Bottomley WW, Jutley J, Wood EJ, Goodfield MD (1995) The effect of calcipotriol on lesional fibroblasts from patients with active morphoea. Acta Denn Venereol, 75: 364–366Google Scholar
  12. Branchet MC, Boisnic S, Bletry O, Robert L, Charron D, Frances C (1992) Expression of HLA class II antigens on skin fibroblasts in scleroderma. Br J Dermatol, 126: 431–435PubMedCrossRefGoogle Scholar
  13. Caca-Biljanovska NG, Vlckova-Laskoska MT, Dervendi DV, Pesic NP, Laskoski DS (1999) Treatment of generalized morphea with oral 1,25-dihydroxyvitamin D3. Adv Exp Med Biol, 455: 299–304PubMedCrossRefGoogle Scholar
  14. Canizares O, Sachs P, Jaimovich L, Torres V (1958) Idiopathic atrophoderma of Pasini and Pierini. Arch Dermatol, 77: 42–59CrossRefGoogle Scholar
  15. Castanet J, Lacour JP, Perrin C, Taillan B, Dubois D, Ortonne JP (1994) Association of eosinophilic fasciitis, multiple morphea and antiphospholipid antibody. Dermatology, 189: 304–307PubMedCrossRefGoogle Scholar
  16. Christianson H, Dorsey C, O’Leary P, Kierland R (1956) Localized scleroderma: a clinical study of twohundred thirty-five cases. Arch Dermatol, 74: 629–639CrossRefGoogle Scholar
  17. Chung MH, Sum J, Morrell MJ, Horoupian DS (1995) Intracerebral involvement in scleroderma en coup de sabre: report of a case with neuropathologic findings. Ann Neurol, 37: 679–681PubMedCrossRefGoogle Scholar
  18. Chung H, Hann S (1997) Lupus panniculitis treated by a combination therapy of hydroxychloroquine and quinacrine. J Dermatol, 24: 569–572PubMedGoogle Scholar
  19. Clemens TL, Adams JS, Horiuchi N, Gilchrest BA, Cho H, Tsuchiya Y, Matsuo N, Suda T, Holick MF (1983) Interaction of 1,25-dihydroxyvitamin-D3 with keratinocytes and fibroblasts from skin of normal subjects and a subject with vitamin-D-dependent rickets, type II: a model for study of the mode of action of 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab, 56: 824–830PubMedCrossRefGoogle Scholar
  20. Cribier B, Faradji T, Le Coz C, Oberling F, Grosshans E (1995) Extracorporeal photochemotherapy in systemic sclerosis and severe morphea. Dermatology, 191: 25–31PubMedCrossRefGoogle Scholar
  21. Cunningham BB, Landells ID, Langman C, Sailer DE, Paller AS (1998) Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol, 39: 211–215PubMedCrossRefGoogle Scholar
  22. Curley RK, Macfarlane AW, Evans S, Woodrow JC (1987) The treatment of linear morphoea with D-penicillamine. Clin Exp Dermatol, 12: 56–57PubMedCrossRefGoogle Scholar
  23. Czarnecki DB, Taft EH (1982) Generalized morphoea successfully treated with salazopyrine. Acta Derm Venereol, 62: 81–82PubMedGoogle Scholar
  24. Daoud MS, Su WP, Leiferman KM, Perniciaro C (1994) Bullous morphea: clinical, pathologic, and immunopathologic evaluation of thirteen cases. J Am Acad Dermatol, 30: 937–943PubMedCrossRefGoogle Scholar
  25. David J, Wilson J, Woo P (1991) Scleroderma “en coup de sabre”. Ann Rheum Dis, 50: 260–262PubMedCrossRefGoogle Scholar
  26. Dehen L, Roujeau JC, Cosnes A, Revuz J (1994) Internal involvement in localized scleroderma. Medicine (Baltimore), 73: 241–245Google Scholar
  27. Diaz-Perez J, Connolly S, Winkelmann R (1980) Disabling pansclerotic morphea of children. Arch Dermatol, 116: 169–173PubMedCrossRefGoogle Scholar
  28. Dillon WI, Saed GM, Fivenson DP (1995) Borrelia burgdorf eri DNA is undetectable by polymerase chain reaction in skin lesions of morphea, scleroderma, or lichen sclerosus et atrophicus of patients from North America. J Am Acad Dermatol, 33: 617–620PubMedCrossRefGoogle Scholar
  29. Doyle JA, Ginsburg WW (1989) Eosinophilic fasciitis. Med Clin North Am, 73: 1157–1166PubMedGoogle Scholar
  30. Drago F, Rampini P, Lugani C, Rebora A (1998) Generalized morphoea after antitetanus vaccination. Clin Exp Dermatol, 23: 142PubMedCrossRefGoogle Scholar
  31. Dubois EL, Chandor S, Friou GJ, Bischel M (1971) Progressive systemic sclerosis (PSS) and localized scleroderma (morphea) with positive LE cell test and unusual systemic manifestations compatible with systemic lupus erythematous (SLE): presentation of 14 cases including one set of identical twins, one with scleroderma and the other with SLE. Review of the literature. Medicine (Baltimore), 50: 199–222Google Scholar
  32. El-Mofty M, Zaher H, Bosseila M, Yousef R, Saad B (2000) Low-dose broad-band UVA in morphea using a new method for evaluation. Photodermatol Photoimmunol Photomed, 16: 43–49PubMedCrossRefGoogle Scholar
  33. Elst EF, Van Suijlekom-Smit LW, Oranje AP (1999) Treatment of linear scleroderma with oral 1,25-dihydroxyvitamin D3 (calcitriol) in seven children. Pediatr Dermatol, 16: 53–58PubMedCrossRefGoogle Scholar
  34. Falanga V, Medsger TA, Reichlin M (1985) High titers of antibodies to single-stranded DNA in linear scleroderma. Arch Dermatol, 121: 345–347PubMedCrossRefGoogle Scholar
  35. Falanga V, Medsger TA, Jr, Reichlin M, Rodnan GP (1986) Linear scleroderma. Clinical spectrum, prognosis, and laboratory abnormalities. Ann Intern Med, 104: 849–857Google Scholar
  36. Falanga V, Medsger TA, Jr, Reichlin M (1987) Antinuclear and anti-single-stranded DNAGoogle Scholar
  37. antibodies in morphea and generalized morphea. Arch Dermatol, 123: 350–353Google Scholar
  38. Falanga V, Medsger TA, Jr (1990) D-penicillamine in the treatment of localized scleroderma. Arch Dermatol, 126: 609–612PubMedCrossRefGoogle Scholar
  39. Fleischmajer R, Nedwich A (1972a) Generalized morphea. I. Histology of the dermis and subcutaneous tissue. Arch Dermatol, 106: 509–514Google Scholar
  40. Fleischmajer R, Prunieras M (1972b) Generalized morphea. II. Electron microscopy of collagen, cells, and the subcutaneous tissue. Arch Dermatol, 106: 515–524Google Scholar
  41. Fleischmajer R, Perlish JS, Krieg T, Timpl R (1981) Variability in collagen and fibronectin synthesis by scleroderma fibroblasts in primary culture. J Invest Dermatol, 76: 400–403PubMedCrossRefGoogle Scholar
  42. Foeldvari I (1998) Progressive linear scleroderma and morphea in a child. J Pediatr, 133: 308PubMedCrossRefGoogle Scholar
  43. Fry A, Alvarellos A, Fink C, Blaw M, Roach E (1992) Intracranial findings in progressive facial hemiatrophy. J Rheumatol, 19: 956–958PubMedGoogle Scholar
  44. Fujimoto M, Sato S, Ihn H, Takehara K (1995) Autoantibodies to the heat-shock protein hsp73 in localized scleroderma. Arch Dermatol Res, 287: 581–585PubMedCrossRefGoogle Scholar
  45. Garcia-Bustinduy M, Noda A, Sanchez R, Gonzalez de Mesa MJ, Guimera F, GarciaMontelongo R (1998) PUVA therapy in localized scleroderma. J Eur Acad Dermatol Venereol, 10: 283–284PubMedCrossRefGoogle Scholar
  46. Garzon M, Paller A (1999) Ultrapotent topical corticosteroids treatment of childhood genital lichen sclerosus. Arch Dermatol, 135: 525–528PubMedCrossRefGoogle Scholar
  47. Gordon GV (1981) Eosinophilic fasciitis. A case report and review of the literature. Cutis, 28: 268, 271–273Google Scholar
  48. Grundmann-Kollmann M, Ochsendorf F, Zollner TM, Spieth K, Sachsenberg-Studer E, Kaufmann R, Podda M (2000) PUVA-cream photochemotherapy for the treatment of localized scleroderma. J Am Acad Dermatol, 43: 675–678PubMedCrossRefGoogle Scholar
  49. Gruss C, Reed JA, Altmeyer P, McNutt NS, Kerscher M (1997a) Induction of interstitial collagenase (MMP-1) by UVA-1 phototherapy in morphea fibroblasts. Lancet, 350: 12951296Google Scholar
  50. Gruss C, Stucker M, Kobyletzki G, Schreiber D, Altmeyer P, Kerscher M (1997b) Low dose UVA1 phototherapy in disabling pansclerotic morphoea of childhood. Br J Dermatol, 136: 293–294PubMedCrossRefGoogle Scholar
  51. Hatamochi A, Ono M, Arakawa M, Takeda K, Ueki H (1992) Analysis of collagen gene expression by cultured fibroblasts in morphoea. Br J Dermatol, 126: 216–221PubMedCrossRefGoogle Scholar
  52. Hauser C, Skaria A, Harms M, Saurat JH (1996) Morphoea following Blaschko’s lines. Br J Dermatol, 134: 594–595PubMedCrossRefGoogle Scholar
  53. Higley H, Persichitte K, Chu S, Waegell W, Vancheeswaran R, Black C(1994) Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud’s phenomenon. Arthritis Rheum, 37: 278–288Google Scholar
  54. Holick MF, Smith E, Pincus S (1987) Skin as the site of vitamin D synthesis and target tissue for 1,25-dihydroxyvitamin D3. Use of calcitriol (1,25-dihydroxyvitamin D3) for treatment of psoriasis. Arch Dermatol, 123: 1677–1683aPubMedCrossRefGoogle Scholar
  55. Hsu S, Lee MW, Carlton S, Kramer EM (1999) Nodular morphea in a linear pattern. Int J Dermatol, 38: 529–530PubMedCrossRefGoogle Scholar
  56. Hiilshnf MM, Pavel S, Breedveld FC, Dijkmans BA, Vermeer BJ (1994) Oral calcitriol as a new therapeutic modality for generalized morphea. Arch Dermatol, 130: 1290–1293CrossRefGoogle Scholar
  57. Humbert PG, Dupond JL, Rochefort A, Vasselet R, Lucas A, Laurent R, Agache P (1990) Localized scleroderma–response to 1,25-dihydroxyvitamin D3. Clin Exp Dermatol, 15: 396–398PubMedCrossRefGoogle Scholar
  58. Humbert P, Aubin F, Dupond JL, Delaporte E (1995) Oral calcitriol as a new therapeutic agent in localized and systemic Scleroderma. Arch Dermatol, 131: 850–851PubMedCrossRefGoogle Scholar
  59. Hunzelmann N, Anders S, Fierlbeck G, Hein R, Herrmann K, Albrecht M, Bell S, Muche R, Wehner-Caroli J, Gaus W, Krieg T (1997) Double-blind, placebo-controlled study of intralesional interferon gamma for the treatment of localized scieroderma. J Am Acad Dermatol, 36: 433–435PubMedCrossRefGoogle Scholar
  60. Hunzelmann N, Scharffetter Kochanek K, Hager C, Krieg T (1998) Management of localized scleroderma. Semin Cutan Med Surg, 17: 34–40PubMedCrossRefGoogle Scholar
  61. Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Fujimoto M, Grotendorst GR, Takehara K (1996) Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol, 106: 729–733PubMedCrossRefGoogle Scholar
  62. Ihn H, Sato S, Fujimoto M, Kikuchi K, Takehara K (1994) Demonstration of interleukin 8 in serum samples of patients with localized scleroderma. Arch Dermatol, 130: 1327–1328PubMedCrossRefGoogle Scholar
  63. Ihn H, Sato S, Fujimoto M, Kikuchi K, Takehara K (1995) Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res, 287: 193–197PubMedCrossRefGoogle Scholar
  64. Ihn H, Sato S, Fujimoto M, Kikuchi K, Takehara K (1996) Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma. Br J Dermatol, 134: 843–7PubMedCrossRefGoogle Scholar
  65. Ihn H, Yazawa N, Kubo M, Yamane K, Sato S, Fujimoto M, Kikuchi K, Soma Y, Tamaki K (2000) Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease. J Rheumatol, 27: 698–702PubMedGoogle Scholar
  66. Itin PH, Schiller P (1999) Double-lined frontoparietal scleroderma en coup de sabre. Dermatology, 199: 185–186PubMedCrossRefGoogle Scholar
  67. Jablonska S (1975a) Facial hemiatrophy and it’s relation to localized scleroderma. In:Google Scholar
  68. Jablonska S (ed) Scleroderma and pseudoscleroderma. PZWL, Warsaw, pp 537–548 Jablonska S (1975b) Localised Scleroderma.In: Jablonska S (ed) Scleroderma and pseudoscleroderma. PZWL, Warsaw, pp 277–303Google Scholar
  69. Jablonska S, Rodnan G (1979) Localized forms of scleroderma. Clin Rheumatol Dis, 5: 215241Google Scholar
  70. Janzen L, Jeffery JR, Gough J, Chalmers IM (1995) Response to methotrexate in a patient with idiopathic eosinophilic fasciitis, morphea, IgM hypergammaglobulinemia, and renal involvement. J Rheumatol, 22: 1967–1970Google Scholar
  71. Jaworsky C (1997) Connective tissue diseases. In: Elder D (ed) Lever’s Histopathology of the Skin. Lippincott-Raven, Philadelphia, pp 253–285Google Scholar
  72. Joly P, Bamberger N, Crickx B, Belaich S (1994) Treatment of severe forms of localized scleroderma with oral corticosteroids: follow-up study on 17 patients. Arch Dermatol, 130: 663–664PubMedCrossRefGoogle Scholar
  73. Jones SM, Mathew CM, Dixey J, Lovell CR, McHugh NJ (1996) VCAM-1 expression on endothelium in lesions from cutaneous lupus erythematosus is increased compared with systemic and localized scleroderma. Br J Dermatol, 135: 678–686PubMedCrossRefGoogle Scholar
  74. Kahari VM, Heino J, Vuorio T, Vuorio E (1988a) Interferon-alpha and interferon-gamma reduce excessive collagen synthesis and procollagen mRNA levels of scleroderma fibroblasts in culture. Biochim Biophys Acta, 968: 45–50PubMedCrossRefGoogle Scholar
  75. Kahari VM, Sandberg M, Kalimo H, Vuorio T, Vuorio E (1988b) Identification of fibroblasts responsible for increased collagen production in localized scleroderma by in situ hybridization. J Invest Dermatol, 90: 664–670PubMedCrossRefGoogle Scholar
  76. Kanekura T, Fukumaru S, Matsushita S, Terasaki K, Mizoguchi S, Kanzaki T (1996) Successful treatment of scleroderma with PUVA therapy. J Dermatol, 23: 455–459PubMedGoogle Scholar
  77. Karrer S, Abels C, Landthaler M, Szeimies RM (2000) Topical photodynamic therapy for localized scleroderma. Acta Derm Venereol, 80: 26–27PubMedCrossRefGoogle Scholar
  78. Kencka D, Blaszczyk M, Jablonska S (1995) Atrophoderma Pasini-Pierini is a primary atrophic abortive morphea. Dermatology, 190: 203–6PubMedCrossRefGoogle Scholar
  79. Kerscher M, Volkenandt M, Meurer M, Lehmann P, Plewig G, Rocken M (1994) Treatment of localised scleroderma with PUVA bath photochemotherapy. Lancet, 343: 1233PubMedCrossRefGoogle Scholar
  80. Kerscher M, Dirschka T, Volkenandt M (1995) Treatment of localised scleroderma by UVA1 phototherapy. Lancet, 346: 1166PubMedCrossRefGoogle Scholar
  81. Kerscher M, Meurer M, Sander C, Volkenandt M, Lehmann P, Plewig G, Rocken M (1996) PUVA bath photochemotherapy for localized scleroderma. Evaluation of 17 consecutive patients. Arch Dermatol, 132: 1280–1282PubMedCrossRefGoogle Scholar
  82. Kerscher M, Volkenandt M, Gruss C, Reuther T, von Kobyletzki G, Freitag M, Dirschka T, Altmeyer P (1998) Low-dose UVA phototherapy for treatment of localized scleroderma. J Am Acad Dermatol, 38: 21–26PubMedCrossRefGoogle Scholar
  83. Kobayashi KA, Lui H, Prendiville JS (1991) Solitary morphea profunda in a 5-year-old girl: case report and review of the literature. Pediatr Dermatol, 8: 292–295PubMedCrossRefGoogle Scholar
  84. Kobayasi T, Serup J (1985) Vascular changes in morphea. Acta Derm Venereol, 65: 116–120PubMedGoogle Scholar
  85. Kobayasi T, Willeberg A, Serup J, Ullman S (1990) Generalized morphea with blisters. A case report. Acta Derm Venereol, 70: 454–456Google Scholar
  86. Koeger AC, Rozenberg S, Fautrel B (1999) Effectiveness of topical calcitriol for localized scleroderma. J Rheumatol, 26: 239–240PubMedGoogle Scholar
  87. Krell JM, Solomon AR, Glavey CM, Lawley TJ (1995) Nodular scleroderma. J Am Acad Dermatol, 32: 343–345PubMedCrossRefGoogle Scholar
  88. Levy JJ, Gassmuller J, Audring H, Brenke A, Albrecht-Nebe H (1993) Imaging subcutaneous atrophy in circumscribed scleroderma with 20 MHz B-scan ultrasound. Hautarzt, 44: 446–451PubMedGoogle Scholar
  89. Liu P, Uziel Y, Chuang S, Silverman E, Krafchik B, Laxer R (1994) Localized scleroderma: Imaging features. Pediatr Radiol, 24: 207–209Google Scholar
  90. Luer W, Jockei D, Henze T, Schipper HI (1990) Progressive inflammatory lesions of the brain parenchyma in localized scleroderma of the head. J Neurol, 237: 379–381PubMedCrossRefGoogle Scholar
  91. Mattila L, Airola K, Ahonen M, Hietarinta M, Black C, Saarialho-Kere U, Kahari VM (1998) Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts. J Invest Dermatol, 110: 416–421PubMedCrossRefGoogle Scholar
  92. McColl G, Buchanan RR (1994) Unilateral scleroderma following ischemic hand injury. J Rheumatol, 21: 380–381PubMedGoogle Scholar
  93. McNiff JM, Glusac EJ, Lazova RZ, Carroll CB (1999) Morphea limited to the superficial reticular dermis: an underrecognized histologic phenomenon. Am J Dermatopathol, 21: 315–319PubMedCrossRefGoogle Scholar
  94. Menni S, Marzano AV, Passoni E (1997) Neurologic abnormalities in two patients with facial hemiatrophy and sclerosis coexisting with morphea. Pediatr Dermatol, 14: 113–116PubMedCrossRefGoogle Scholar
  95. Micalizzi C, Parodi A, Rebora A (1994) Morphea with nodular lesions. Br J Dermatol, 131: 298–300PubMedCrossRefGoogle Scholar
  96. Micalizzi C, Parodi A, Rebora A (1996) Generalized bullous morphoea. Efficacy of salazopyrin. Clin Exp Dermatol, 21: 246–247Google Scholar
  97. Miller J (1992) The fasciitis-morphea complex in children. Am J Dis Child, 146: 733–736PubMedGoogle Scholar
  98. Mitchet C, Doyle J, Ginsburg W (1981) Eosinophilic fascitis: report of 15 cases. Mayo Clin Proc, 56: 27–34Google Scholar
  99. Mizutani H, Yoshida T, Nouchi N, Hamanaka H, Shimizu M (1999) Topical tocoretinate improved hypertrophie scar, skin sclerosis in systemic sclerosis and morphea. J Dermatol, 26: 11–7PubMedGoogle Scholar
  100. Mohrenschlager M, Jung C, Ring J, Abeck D (1999) Effect of penicillin G on corium thickness in linear morphea of childhood: An analysis using ultrasound technique. Pediatr Dermatol, 16: 314–316Google Scholar
  101. Moller R, Serup J, Ammitzboll T (1985) Glycosaminoglycans in localized scleroderma (morphoea). Connect Tissue Res, 13: 227–236PubMedCrossRefGoogle Scholar
  102. Monteiro MR, Murphy EE, Galaria NA, Whitaker-Menezes D, Murphy GF (2000) Cytological alterations in dermal dendrocytes in vitro: evidence for transformation to a non-dendritic phenotype. Br J Dermatol, 143: 84–90PubMedCrossRefGoogle Scholar
  103. Morison WL (1997) Psoralen UVA therapy for linear and generalized morphea. J Am Acad Dermatol, 37: 657–659PubMedCrossRefGoogle Scholar
  104. Morita A, Werfel T, Stege H, Ahrens C, Karmann K, Grewe M, Grether-Beck S, Ruzicka T, Kapp A, Klotz LO, Sies H, Krutmann J (1997) Evidence that singlet oxygen-induced human T helper cell apoptosis is the basic mechanism of ultraviolet-A radiation photo-therapy. J Exp Med, 186: 1763–1768PubMedCrossRefGoogle Scholar
  105. Mork NJ (1981) Clinical and histopathologic morphea with immunological evidence of lupus erythematosus: a case report. Acta Derm Venereol, 61: 367–368PubMedGoogle Scholar
  106. Morley SM, Gaylarde PM, Sarkany I (1985) Epidermal thickness in systemic sclerosis and morphoea. Clin Exp Dermatol, 10: 51–57PubMedCrossRefGoogle Scholar
  107. Moynahan EJ (1973) Morphoea (localized cutaneous scleroderma) treated with low-dosage penicillamine (4 cases, including coup de sabre). Proc R Soc Med, 66: 1083–1085PubMedGoogle Scholar
  108. Narvaez D, Kanitakis J, Faure M, Claudy A (1996) Immunohistochemical study of CD34-positive dendritic cells of human dermis. Am J Dermatopathol, 18: 283–288PubMedCrossRefGoogle Scholar
  109. Neldner KH (1978) Treatment of localized linear scleroderma with phenytoin. Cutis, 22: 569–572PubMedGoogle Scholar
  110. Neuhofer J, Fritsch P (1984) Treatment of localized scleroderma and lichen sclerosus with etretinate. Acta Derm Venereol, 64: 171–174PubMedGoogle Scholar
  111. O’Leary P, Montgomery H, Ragsdale W (1957) Dermatohistopathology of various types of scleroderma. Arch Dermatol, 75: 78–87CrossRefGoogle Scholar
  112. Perlish JS, Lemlich G, Fleischmajer R (1988) Identification of collagen fibrils in scleroderma skin. J Invest Dermatol, 90: 48–54PubMedCrossRefGoogle Scholar
  113. Person JR, Su WP (1979) Subcutaneous morphoea: a clinical study of sixteen cases. Br J Dermatol, 100: 371–380PubMedCrossRefGoogle Scholar
  114. Peter RU, Ruzicka T, Eckert F (1991) Low-dose cyclosporine A in the treatment of disabling morphea. Arch Dermatol, 127: 1420–1421PubMedCrossRefGoogle Scholar
  115. Peterson LS, Nelson AM, Su WP (1995) Classification of morphea (localized scleroderma). Mayo Clin Proc, 70: 1068–1076PubMedCrossRefGoogle Scholar
  116. Peterson LS, Nelson AM, Su WP, Mason T, O’Fallon WM, Gabriel SE (1997) The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. J Rheumatol, 24: 73–80PubMedGoogle Scholar
  117. Rai R, Handa S, Gupta S, Kumar B (2000) Bilateral en coup de sabre-a rare entity. Pediatr Dermatol, 17: 222–224PubMedCrossRefGoogle Scholar
  118. Rigby WF, Denome S, Fanger MW (1987) Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. J Clin Invest, 79: 1659–1664Google Scholar
  119. Rigby WF, Waugh MG (1992) Decreased accessory cell function and costimulatory activity by 1,25-dihydroxyvitamin D3-treated monocytes. Arthritis Rheum, 35: 110–119PubMedCrossRefGoogle Scholar
  120. Rodnan GP, Lipinski E, Luksick J (1979) Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum, 22: 130–140PubMedCrossRefGoogle Scholar
  121. Rose CD, Fawcett PT, Gibney K, Doughty RA, Singsen BH (1994) Serial measurements of soluble interleukin 2 receptor levels (sIL2-R) in children with juvenile rheumatoid arthritis treated with oral methotrexate. Ann Rheum Dis, 53: 471–474PubMedCrossRefGoogle Scholar
  122. Rosenberg AM, Uziel Y, Krafchik BR, Hauta SA, Prokopchuk PA, Silverman ED, Laxer RM (1995) Antinuclear antibodies in children with localized scleroderma. J Rheumatol, 22: 2337–2343PubMedGoogle Scholar
  123. Ruffatti A, Peserico A, Rondinone R, Calligaro A, Del Ross T, Ghirardello A, Germino M, Todesco S (1991) Prevalence and characteristics of anti-single-stranded DNA antibodies in localized scleroderma. Comparison with systemic lupus erythematosus. Arch Dermatol, 127: 1180–1183Google Scholar
  124. Sakuraoka K, Tajima S, Nishikawa T (1992) Progressive facial hemiatrophy: report of five cases and biochemical analysis of connective tissue. Dermatology, 185: 196–201PubMedCrossRefGoogle Scholar
  125. Salmon-Ehr V, Serpier H, Nawrocki B, Gillery P, Clavel C, Kalis B, Birembaut P, Maquart FX (1996) Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in fibrosis. Arch Dermatol, 132: 802–806Google Scholar
  126. Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K (1994) Antigen specificity of antihistone antibodies in localized scleroderma. Arch Dermatol, 130: 1273–1277PubMedCrossRefGoogle Scholar
  127. Sato S, Fujimoto M, Kikuchi K, Ihn H, Tamaki K, Takehara K (1996a) Elevated soluble CD23 levels in the sera from patients with localized scleroderma. Arch Dermatol Res, 288: 74–88PubMedCrossRefGoogle Scholar
  128. Sato S, Fujimoto M, Kikuchi K, Ihn H, Tamaki K, Takehara K (1996b) Soluble CD4 and CD8 in serum from patients with localized scleroderma. Arch Dermatol Res, 288: 358–362PubMedCrossRefGoogle Scholar
  129. Schaffer JV, Carroll C, Dvoretsky I, Huether MJ, Girardi M (2000) Postirradiation morphea of the breast presentation of two cases and review of the literature. Dermatology, 200: 67–71PubMedCrossRefGoogle Scholar
  130. Scharffetter-Kochanek K, Goldermann R, Lehmann P, Holzle E, Goerz G (1995) PUVA therapy in disabling pansclerotic morphoea of children. Br J Dermatol, 132: 830–831PubMedCrossRefGoogle Scholar
  131. Scharffetter K, Lankat-Buttgereit B, Krieg T (1988) Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest, 18: 9–17PubMedCrossRefGoogle Scholar
  132. Schiener R, Behrens-Williams SC, Gottlober P, Pillekamp H, Peter RU, Kerscher M (2000) Eosinophilic fasciitis treated with psoralen-ultraviolet A bath photochemotherapy. Br J Dermatol, 142: 804–807PubMedCrossRefGoogle Scholar
  133. Seitz M, Loetscher P, Dewald B, Towbin H, Rordorf C, Gallati H, Baggiolini M, Gerber NJ (1995) Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. Br J Rheumatol, 34: 602–9PubMedCrossRefGoogle Scholar
  134. Seitz M, Zwicker M, Loetscher P (1998) Effects of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes. Arthritis Rheum, 41: 2032–2038PubMedCrossRefGoogle Scholar
  135. Seyger MM, van den Hoogen FH, de Boo T, de Jong EM (1997) Reliability of two methods to assess morphea: skin scoring and the use of a durometer. J Am Acad Dermatol, 37: 793796Google Scholar
  136. Seyger MM, van den Hoogen FH, de Boo T, de Jong EM (1998) Low-dose methotrexate in the treatment of widespread morphea. J Am Acad Dermatol, 39: 220–225PubMedCrossRefGoogle Scholar
  137. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G (1996) Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest, 98: 785–792PubMedCrossRefGoogle Scholar
  138. Shulman L (1974) Diffuse fasciitis with hypergammaglobulinemia and eosinophilia: a new syndrome? Clinical Reaserch, 23: 443AGoogle Scholar
  139. Silman A, Jannini S, Symmons D, Bacon P (1988) An epidemiological study of scleroderma in the West Midlands. Br J Rheumatol, 27: 286–290PubMedCrossRefGoogle Scholar
  140. Skobieranda K, Helm KF (1995) Decreased expression of the human progenitor cell antigen (CD34) in morphea. Am J Dermatopathol, 17: 471–475PubMedCrossRefGoogle Scholar
  141. Soma Y, Fujimoto M (1998). Frontoparietal scleroderma (en coup de sabre) following Blaschko’s lines. J Am Acad Dermatol, 38: 366–368PubMedCrossRefGoogle Scholar
  142. Soma Y, Tamaki T, Kikuchi K, Abe M, Igarashi A, Takehara K, Ishibashi Y (1993) Coexistence of morphea and systemic sclerosis. Dermatology, 186: 103–105PubMedCrossRefGoogle Scholar
  143. Stava Z, Kobikova M (1977) Salazopyrin in the treatment of scleroderma. Br J Dermatol, 96: 541–544PubMedCrossRefGoogle Scholar
  144. Stefanec T (2000) Endothelial apoptosis: could it have a role in the pathogenesis and treatment of disease? Chest, 117: 841–854PubMedCrossRefGoogle Scholar
  145. Stege H, Berneburg M, Humke S, Klammer M, Grewe M, Grether-Beck S, Boedeker R, Diepgen T, Dierks K, Goerz G, Ruzicka T, Krutmann J (1997) High-dose UVA1 radiation therapy for localized scleroderma. J Am Acad Dermatol, 36: 938–944PubMedCrossRefGoogle Scholar
  146. Steger JW, Matthews JH (1999) UVA therapy for scleroderma. J Am Acad Dermatol, 40: 787–788PubMedCrossRefGoogle Scholar
  147. Su WP, Person JR (1981) Morphea profunda. A new concept and a histopathologic study of 23 cases. Am J Dermatopathol, 3: 251–260PubMedCrossRefGoogle Scholar
  148. Su WP, Greene SL (1986) Bullous morphea profunda. Am J Dermatopathol, 8: 144–147PubMedCrossRefGoogle Scholar
  149. Takehara K, Moroi Y, Nakabayashi Y, Ishibashi Y (1983) Antinuclear antibodies in localized scleroderma. Arthritis Rheum, 26: 612–616PubMedCrossRefGoogle Scholar
  150. Taveira M, Selores M, Costa V, Massa A (1999) Generalized morphea end lichen sclerosus et atrophicus successfully treated with sulphasalazine. J Eur Acad Dermatol Venereol, 12: 283–284PubMedCrossRefGoogle Scholar
  151. Todd DJ, Askari A, Ektaish E (1998) PUVA therapy for disabling pansclerotic morphoea of children. Br J Dermatol, 138: 201–202PubMedCrossRefGoogle Scholar
  152. Torres JE, Sanchez JL (1998) Histopathologic differentiation between localized and systemic scleroderma. Am J Dermatopathol, 20: 242–245PubMedCrossRefGoogle Scholar
  153. Tuffanelli DL (1998) Localized scleroderma. Semin Cutan Med Surg, 17: 27–33PubMedCrossRefGoogle Scholar
  154. Uitto J, Santa Cruz DJ, Bauer EA, Eisen AZ (1980) Morphea and lichen sclerosus et atrophií,üS. Clinical and histopathologic studies in patients with combined features. J Am Aced Dermatol, 3: 271–279Google Scholar
  155. Umbert P, Winkelmann RK (1978) Concurrent localized scleroderma and discoid lupus erythematosus. Cutaneous ‘mixed’ or ’overlap’ syndrome. Arch Dermatol, 114: 1473–1478Google Scholar
  156. Uziel Y, Krafchik BR, Silverman ED, Thorner PS, Laxer RM (1994) Localized scleroderma in childhood: a report of 30 cases. Semin Arthritis Rheum, 23: 328–340PubMedCrossRefGoogle Scholar
  157. Uziel Y, Feldman BM, Krafchik BR, Yeung RS, Laxer RM (2000) Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr, 136: 91–95PubMedCrossRefGoogle Scholar
  158. van Bergen BH, van Dooren-Greebe RJ, Fiselier TJ, Koopman RJ (1997) D-penicillamine in treatment of scleroderma “en coup de sabre”. Hautarzt, 48: 42–44PubMedCrossRefGoogle Scholar
  159. van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB (1996) Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol, 35: 364–372PubMedCrossRefGoogle Scholar
  160. Venneker GT, Das PK, Naafs B, Tigges AJ, Bos JD, Asghar SS (1994) Morphoea lesions are associated with aberrant expression of membrane cofactor protein and decay accelerating factor in vascular endothelium. Br J Dermatol, 131: 237–242PubMedCrossRefGoogle Scholar
  161. Wach F, Ullrich H, Schmitz G, Landthaler M, Hein R (1995) Treatment of severe localized scleroderma by plasmapheresis–report of three cases. Br J Dermatol, 133: 605–609PubMedCrossRefGoogle Scholar
  162. Wakelin SH, James MP (1995) Zosteriform atrophoderma of Pasini and Pierini. Clin Exp Dermatol, 20: 244–246PubMedCrossRefGoogle Scholar
  163. Weedon D (1997) Disorders of collagen. In: Skin Pathology, Churchill Livingstone, HongKong, pp 288–293Google Scholar
  164. Weide B, Walz T, Garbe C (2000) Is morphoea caused by Borrelia burgdorferi? A review. Br J Dermatol, 142: 636–644PubMedCrossRefGoogle Scholar
  165. Whittaker SJ, Smith NP, Jones RR (1989) Solitary morphoea profunda. Br J Dermatol, 120: 431–440PubMedCrossRefGoogle Scholar
  166. Winkelmann RK, Connolly SM, Doyle JA (1982) Carpal tunnel syndrome in cutaneous connective tissue disease: generalized morphea, lichen sclerosus, fasciitis, discoid lupus erythematosus, and lupus panniculitis. J Am Acad Dermatol, 7: 94–99PubMedCrossRefGoogle Scholar
  167. Winkelmann R (1985) Localized cutaneous scleroderma. Seminars in Dermatology, 4: 90103Google Scholar
  168. Wlaschek M, Briviba K, Stricklin GP, Sies H, Scharffetter-Kochanek K (1995) Singlet oxygen may mediate the ultraviolet A-induced synthesis of interstitial collagenase. J Invest Dermatol, 104: 194–198PubMedCrossRefGoogle Scholar
  169. Wollenberg A, Baumann L, Plewig G (1995) Linear atrophoderma of Moulin• a disease which follows Blaschko’s lines. Br J Dermatol, 135: 277–279CrossRefGoogle Scholar
  170. Wollina U, Looks A, Schneider R, Maak B (1998) Disabling morphoea of childhood-beneficial effect of intravenous immunoglobulin therapy. Clin Exp Dermatol, 23: 292–293PubMedCrossRefGoogle Scholar
  171. Wuthrich RC, Roenigk HH, Steck WD (1975) Localized scleroderma. Arch Dermatol, 111: 98–100PubMedCrossRefGoogle Scholar
  172. Yamaguchi K, Takeuchi I, Yoshii N, Gushi A, Kanekura T, Kanzaki T (1998) The discrepancy in hardness between clinical and histopathological findings in localized scleroderma treated with PUVA. J Dermatol, 25: 544–546PubMedGoogle Scholar
  173. Yamanaka CT, Gibbs NF (1999) Trauma-induced linear scleroderma. Cutis, 63: 29–32PubMedGoogle Scholar
  174. Yamane K, Ihn H, Kubo M, Yazawa N, Kikuchi K, Soma Y, Tamaki K (2000) Increased serum levels of soluble vascular cell adhesion molecule 1 and E-selectin in patients with localized scleroderma. J Am Acad Dermatol, 42: 64–69PubMedCrossRefGoogle Scholar
  175. Young EM, Jr, Barr RJ (1985) Sclerosing dermatoses. J Cutan Pathol, 12: 426–441PubMedCrossRefGoogle Scholar
  176. Zheng XY, Zhang JZ, Tu P, Ma SQ (1998) Expression of platelet-derived growth factor Bchain and platelet-derived growth factor beta-receptor in fibroblasts of scleroderma. J Dermatol Sci, 18: 90–97PubMedCrossRefGoogle Scholar
  177. Artlett CM, Smith CB, Jimenez SA (1998) Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 338: 1186–1191PubMedCrossRefGoogle Scholar
  178. Badesch D, Tapson VF, McGoon MD (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Int Med 132: 425434Google Scholar
  179. Black CM, Silman SJ, Herrick AI (1998) Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double blind, placebo-controlled trial. Arthritis Rheum 42: 299–305CrossRefGoogle Scholar
  180. Blockmans D, Beyens G, Verhaege R (1996) Predictive value of nailfold capillaroscopy in the diagnosis of connective tissue diseases. Clin Rheumatol 15: 148–153PubMedCrossRefGoogle Scholar
  181. Bottomley WW, Goodfield MJ, Sheehan-Dare RA (1996) Digital calcification in systemic sclerosis: effective treatment with good tissue preservation using the carbon dioxide laser. Br J Dermatol 135: 302–302PubMedCrossRefGoogle Scholar
  182. Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM (1998) Anti-RNA Polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 37: 15–20PubMedCrossRefGoogle Scholar
  183. Chang YJ, Spiera H (1999) Renal transplantation in scleroderma. Medicine 78: 382–385PubMedCrossRefGoogle Scholar
  184. Clements PJ, Lachenbruch PA, Ng SC (1990) Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 33: 1256–1263Google Scholar
  185. Clements PJ, Furst DE (1997) Choosing appropriate patients with systemic sclerosis for treatment by autologous stem cell transplantation. J Rheumatol 24: 85–88Google Scholar
  186. Clements PJ, Furst DE, Wong WK (1999) High dose versus low dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two year, double blind, randomized, controlled clinical trial. Arthritis Rheum 42: 1194–203PubMedCrossRefGoogle Scholar
  187. Denton CP, Sweny P Abdulla A, Black CM (1994) Acute renal failure occurring in sclero- derma treated with cyclosporin A: a report of three cases. Br J Rheumatol 33: 90–92PubMedCrossRefGoogle Scholar
  188. Duncan MR, Hasan A, Berman B (1995) Pentoxifylline, pentifylline and interferons decrease type I and III procollagen mRNA levels in dermal fibroblasts: evidence for mediation by nuclear factor 1 downregulation. J Invest Dermatol 104: 282–286PubMedCrossRefGoogle Scholar
  189. Dziadzio M, Denton CP Smith R (1999) Losartan therapy for raynauds phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel group, controlled trial. Arthritis Rheum 42: 2646–2455PubMedCrossRefGoogle Scholar
  190. Eckes B, Mauch C, Huppe G, Krieg T (1996) Differential regulation of transcription and transcript stability of pro a1(I) collagen and fibronectin in activated fibroblasts derived from patients with systemic sclerosis. Biochem J 315: 549–553PubMedGoogle Scholar
  191. Enomoto, Mekkes JR, Bossuyt PM (1999) Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis). J Am Acad Dermatol 41: 915–922PubMedCrossRefGoogle Scholar
  192. Evans PC, Lambert N, Maloney S (1999) Long term fetal microchimerism in peripheral blood mononuclear scell subsets in healthy women and women with scleroderma. Blood 93: 2033–2037PubMedGoogle Scholar
  193. Fritzler MJ (1993) Autoantibodies in scleroderma. J Dermatol 20: 257–268PubMedGoogle Scholar
  194. Furst DE, Clements PJ, Steen VD (1998) The modified rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 25: 84–88PubMedGoogle Scholar
  195. Genth E, Mierau R, Genetzky P (1990) Immunogenetic associations of scleroderma-related antinuclear antibodies. Arthritis Rheum 33: 657–665PubMedCrossRefGoogle Scholar
  196. Jablonska S, Blaszyk M (1999) Scleroderma Overlap Syndromes. Adv Exp Med Biol 455: 8592Google Scholar
  197. Janowsky EC, Kupper LL, Hulka BS (2000) Meta-analyses of the relation between silicone breast implants and the risk of connective tissue. N Engl J Med 342: 781–790PubMedCrossRefGoogle Scholar
  198. Haustein UF, Anderegg U (1998) Silica induced scleroderma–clinical and experimental aspects. J Rheumatol 25: 1917–1926PubMedGoogle Scholar
  199. Heickendorff L, Zachariae H, Bjerring P, Halkier-Sorensen L, Sondergaard K (1995) The use of serologic markers for collagen synthesis and degradation in systemic sclerosis. J Am Acad Dermatol 32: 584–588PubMedCrossRefGoogle Scholar
  200. Herrmann K, Heckmann M, Kulozik M, Haustein UF, Krieg T (1991) Steady state mRNA levels of collagens I,III, fibronectin and collagenase in skin biopsies of systemic sclerosis patients. J Invest Dermatol 97: 219–225PubMedCrossRefGoogle Scholar
  201. Herrmann G, Wlaschek M, Lange TS, Prenzel K, Goerz G, Scharffetter-Kochanek K (1993) UVA irradiation stimulates the synthesis of various matrix-metalloproteinases ( MMPs) in cultured human fibroblasts. Exp Dermatol 2: 92–97Google Scholar
  202. Hoeper MM et al. (2000) Long term treatment of primary pulmonary hypertension with aerolized iloprost, a prostacyclin analogue. N Engl J Med 342: 1866–70PubMedCrossRefGoogle Scholar
  203. Hunzelmann N, Anders S, Fierlbeck G, Hein R, Herrmann K, Albrecht M, Bell S, Thur J, Muche R, Adelmann-Grill B,Wehner-Caroli J, Gaus W, Krieg T (1997) Systemic scleroderma: multicenter trial of one year treatment with recombinant interferon-gamma. Arch Dermatol 133: 609–613Google Scholar
  204. Hunzelmann N, Risteli J, Risteli L, Sacher C, Black CM, Krieg T (1998a) Increased circulating concentrations of the type I collagen specific degradation product ICTP in systemic sclerosis reflect the extent of skin involvement: A new serum marker for clinical severity in SSc patients. Br J Dermatol 139: 1020–1025Google Scholar
  205. Hunzelmann N, Scharfetter-Kochanek K, Hager C, Krieg T (1998b) Management of localized scleroderma. Sem Cutan Med Surg 17: 34–41CrossRefGoogle Scholar
  206. Igarashi A, Nashiro K, Kikuchi K (1995) Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol 105: 280–284PubMedCrossRefGoogle Scholar
  207. Jimenez SA and Saitta B (2000) Alterations in the regulation of expression of the al(I) collagen gene (COL1A1) in systemic sclerosis (scleroderma). Springer Semin Immunopathol 21: 397–414Google Scholar
  208. Kahaleh MB, Sultany GL, Smith EA, Huffstetter JE, Loadholt CB, LeRoy EC (1986) A modified scleroderma skin scoring method. Clin Exp Rheumatol 4: 367–369PubMedGoogle Scholar
  209. Kahaleh M, Fan PS (1997) Mechanism of serum mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera. Clin Immunol Immunopathol 83: 32–40PubMedCrossRefGoogle Scholar
  210. Kerscher M, Meurer M, Sander C, Volkenandt M, Lehmann P, Plewig G, Röcken M (1996) PUVA bath photochemotherapy for localized scleroderma. Arch Dermatol 132: 1280–1282PubMedCrossRefGoogle Scholar
  211. Kulozik M, Hogg A, Lankat-Buttgereit B, Krieg T (1990) Co-localization of transforming growth factor 62 with a1(1) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest 86: 917–921PubMedCrossRefGoogle Scholar
  212. LeRoy EC (1974) Increased collagen synthesis by scleroderma fibroblasts in vitro. J Clin Invest 54: 880–889PubMedCrossRefGoogle Scholar
  213. Lunardi C (2000) Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nature Med 6: 1183–1186PubMedCrossRefGoogle Scholar
  214. Majewski S, Hunzelmann N, Johnson JP, Jung C, Mauch C, Ziegler-Heitbrock H, Riethmüller G, Krieg T (1991) Expression of intercellular adhesion molecule-1 (ICAM-1) on fibroblasts in the skin of patients with systemic sclerosis. J Invest Dermatol 97: 667–671PubMedCrossRefGoogle Scholar
  215. Marguerie C (1992) The clinical and immunogenetic features of patients with autoantibodies to the nucleolar anitgen PM-Scl. Medicine 71: 327–336PubMedCrossRefGoogle Scholar
  216. Maricq H, LeRoy E, Dangelo W (1980) Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum 23: 183–189PubMedCrossRefGoogle Scholar
  217. Mauch C (1998) Regulation of connective tissue turnover by cell-matrix interactions. Arch Dermatol Res 290: S30–36PubMedCrossRefGoogle Scholar
  218. McCormick LL, Zhang Y, Tootell E, Gilliam AC (1999) Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 163: 5693–5699PubMedGoogle Scholar
  219. McKown KM, Carbone LD, Bustillo J (2000) Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen. Arthritis Rheum 43: 1054–1061PubMedCrossRefGoogle Scholar
  220. Perlish JS, Lemlich G, Fleischmajer R (1988) Identification of collagen fibrils in scleroderma skin. J Invest Dermatol 90: 48–54PubMedCrossRefGoogle Scholar
  221. Pigula FA, Griffith BP, Zenati MA (1997) Lung transplantation for respiratory failure resulting from systemic disease. Ann Thorac Surg 64: 1630–1634PubMedCrossRefGoogle Scholar
  222. Poormoghim H, Lucas M, Fertig N, Medsger TA (2000) Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty eight patients. Arthritis Rheum 43: 444–451PubMedCrossRefGoogle Scholar
  223. Pope J, Bellamy N, Seibold J (1998) A controlled trial of methotrexate versus placebo in early diffuse scleroderma - preliminary analysis. Arthritis Rheum 41: S420Google Scholar
  224. Pope J, Fenlon D, Thompson A (2000) Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2: CD000953Google Scholar
  225. Prescott RJ, Freemont A, Jones C (1992) Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166: 255–263PubMedCrossRefGoogle Scholar
  226. Rook AH, Freundlich B, Jegasothy BV (1992) Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. Arch Dermatol 128: 337–346Google Scholar
  227. Scharffetter K, Lankat-Buttgereit B, Krieg T (1988) Localization of collagen mRNA in normal and scleroderma skin by in situ hybridization. Eur J Clin Invest 18: 9–17PubMedCrossRefGoogle Scholar
  228. Scharffetter K, Wlaschek M, Hogg A, Bolsen K, Schothorst A, Goerz G, Krieg T, Plewig G (1991) UVA irradiation induces collagenase in human dermal fibroblasts in vitro and in vivo. Arch Dermatol Res 283: 506–511PubMedCrossRefGoogle Scholar
  229. Seibold J (1994) Systemic sclerosis. In: Klipped J, Dieppe P, Mosby St. Louis (Eds) Rheumatology, 8.1–8. 14Google Scholar
  230. Seibold J, Korn J, Simms R (2000) Recombinant human relaxin in the treatment of scleroderma. A randomized, double blind, placebo-controlled study. Ann Int Med 132: 871–879Google Scholar
  231. Sgonc R, Gruschwitz M, Dietrich H (1996) Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 98: 785–792PubMedCrossRefGoogle Scholar
  232. Shi-Wen X, Pennington D, Holmes A (2000) Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis. Exp Cell Res 25: 213–224Google Scholar
  233. Sjogren RW (1996) Gastrointestinal features of scleroderma. Curr Opin Rheumatol 8: 569–575PubMedCrossRefGoogle Scholar
  234. Steen VD, Constantino JP, Shapiro AP, Medsger TA (1990) Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme ( ACE) inhibitors. Ann Int Med 113: 352–357Google Scholar
  235. Steen VD, Follansbee WP, Conte CG, Medsger TA (1996) Thallium perfusion defects predict subsequent cardiac dysfunction in patients with systemic sclerosis. Arthritis Rheum 39: 677–681PubMedCrossRefGoogle Scholar
  236. Steen VD, Medsger TA (1998) Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 41: 1613–1619PubMedCrossRefGoogle Scholar
  237. Stege H, Berneburg M, Humke S (1997) High-dose UVA, radiation therapy for localized scleroderma. J Am Acad Dermatol 36: 938–944PubMedCrossRefGoogle Scholar
  238. Stone PJ, Korn JH, North H, Lally EV, Miller LC, Tucker LB, Strongwater S, Snider GL, Franzblau C (1995): Cross-linked elastin and collagen degradation products in the urine of patients with scleroderma. Arthritis Rheum 38: 517–524PubMedCrossRefGoogle Scholar
  239. Straniero NR, Furst DE (1989) Environmentally induced systemic sclerosis like illness. Baillieres Clin Rheumatol 3: 63–79PubMedCrossRefGoogle Scholar
  240. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnosis and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23: 581–590CrossRefGoogle Scholar
  241. Tyndall A, Black C, Finke J, Peter H, Gratwohl A (1997) Treatment of systemic sclerosis with autologous hemopoetic stem cell transplantation. The Lancet 349: 254–356CrossRefGoogle Scholar
  242. Uitto J, Bauer EA, Eisen AZ (1979) Scleroderma. Increased biosynthesis of triple helical type I and type III procollagen associated with unaltered expression of collagenase by skin fibroblasts in culture. J Clin Invest 64: 921–930Google Scholar
  243. van den Hoogen FH, Boerbooms AM, Swaak AJ (1996) Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double blind trial, followed by a 24 week observation trial. Br J Rheumatol 35: 364–372PubMedCrossRefGoogle Scholar
  244. White B, Bauer EA, Goldsmith LA (1995) Guidelines for clinical trials in systemic sclerosis (scleroderma). I. disease modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic sclerosis. Arthritis Rheum 38: 351–360Google Scholar
  245. White B, Moore WC, Wigley FM (2000) Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Int Med 132: 947–954PubMedGoogle Scholar
  246. Williams HJ, Alarcon GS, Joks R (1999) Early undifferentiated connective tissue disease. VI an inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. J Rheumatol 26: 816–825PubMedGoogle Scholar
  247. Zachariae H, Halkier-Sorensen L, Bjerring P, Heickendorff L (1996) Treatment of ischemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis. Acta Derm Venereol 76: 236–238PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2001

Authors and Affiliations

  • Catherine H. Orteu
  • Jan P. Dutz
  • Nicolas Hunzelmann
  • Thomas Krieg

There are no affiliations available

Personalised recommendations